09:17 AM EDT, 06/11/2025 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Wednesday that results from its phase 3b Apex trial demonstrated that monoclonal antibody Tremfya "significantly reduced" signs and symptoms of active psoriatic arthritis and inhibited progression of joint structural damage at 24 weeks compared with placebo.

The company said 67% and 63% of patients who received Tremfya every four weeks and every eight weeks, respectively, experienced no radiographic progression, compared with 53% in the placebo group.

Johnson & Johnson ( JNJ ) said the results from the trial were "consistent" with Tremfya's safety profile and no new safety signals were detected.

Tremfya is approved in the US to treat adults with active psoriatic arthritis, but not for dosing every four weeks, the company said. The drug is also approved for moderate-to-severe plaque psoriasis, ulcerative colitis, and Crohn's disease.